Literature DB >> 28477388

Phenotypic and molecular differences between giant-cell tumour of soft tissue and its bone counterpart.

Irene Mancini1, Alberto Righi2, Marco Gambarotti2, Piero Picci2, Angelo P Dei Tos3, Steven D Billings4, Lisa Simi1, Alessandro Franchi5.   

Abstract

AIMS: Giant-cell tumour (GCT) of soft tissue (GCT-ST) is a primary soft tissue neoplasm that is histologically similar to GCT of bone (GCT-B). Recently, it has been reported that >90% of GCT-Bs have a driver mutation in the H3F3A gene. As the relationship between GCT-ST and GCT-B is unclear, the aim of this study was to compare a series of GCT-STs and GCT-Bs with regard to the presence of H3F3A mutations and several immunophenotypic markers. METHODS AND
RESULTS: Eight GCT-STs were retrieved from our institutional archives. Fifteen GCT-Bs served as controls. Direct sequencing for H3F3A mutations in coding regions between codons 1 and 42, including the hotspot codons (28, 35, and 37), was performed on DNA extracted from formalin-fixed paraffin-embedded tissue. Tumours were studied immunohistochemically for the expression of CD14, CD33, RANKL, RANK, p63, and the osteoblastic markers SATB2 and RUNX2. None of the seven GCT-STs that could be analysed showed H3F3A mutations, whereas 14 GCT-Bs (93.3%) were mutated. All eight GCT-STs were positive for RANK and RUNX2, whereas RANKL and SATB2 were detected in only two cases (25%). CD14 was detected only in mononuclear elements, whereas multinucleated giant cells and a proportion of the mononuclear population expressed CD33. Few mononuclear cells of GCT-STs expressed p63. In comparison, GCT-Bs showed higher expression of p63 (14 of 15 cases with >50% of positive mononuclear cells), RANKL, and SATB2, whereas CD14, CD33, RANK and RUNX2 were similarly expressed.
CONCLUSIONS: Although GCT-ST and GCT-B are similar in histological appearance, our results indicate that they are immunophenotypically and genetically distinct.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  H3F3A gene; Immunohistochemistry; bone; giant-cell tumour; soft tissue

Mesh:

Substances:

Year:  2017        PMID: 28477388     DOI: 10.1111/his.13249

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

2.  Giant Cell Tumor of Distal Radius After Open Reduction Internal Fixation for Distal Radius Fracture.

Authors:  Danielle C Marshall; Roger J Bartolotta; Roberto A Garcia; Meera Hameed; Dean G Lorich; Edward A Athanasian; Duretti T Fufa
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2017-10-17

3.  Giant Cell Tumor of Soft Tissue-A Rare Cause of Mass in the Liver: A Case Report.

Authors:  Piaopiao Chen; Qiang Hu; Jinfeng Wu
Journal:  Front Surg       Date:  2022-04-27

4.  Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors.

Authors:  Andrew L Folpe; Kemal Kösemehmetoğlu; Abbas Agaimy; Michael Michal; Robert Stoehr; Fulvia Ferrazzi; Pavel Fabian; Michal Michal; Alessandro Franchi; Florian Haller
Journal:  Mod Pathol       Date:  2021-03-19       Impact factor: 7.842

5.  Cytoplasmic sharing through apical membrane remodeling.

Authors:  Nora G Peterson; Benjamin M Stormo; Kevin P Schoenfelder; Juliet S King; Rayson Rs Lee; Donald T Fox
Journal:  Elife       Date:  2020-10-14       Impact factor: 8.140

6.  Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series.

Authors:  Francesca Ambrosi; Alberto Righi; Stefania Benini; Giovanna Magagnoli; Ilaria Chiaramonte; Marco Manfrini; Alessandro Gasbarrini; Tommaso Frisoni; Marco Gambarotti
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.